Valeant Beats on All Fronts – Analyst Blog

By | November 5, 2012
0 Comment

Valeant Pharmaceuticals International ‘s ( VRX )  third quarter 2012 earnings of $1.11 per share (excluding special items but including stock-based compensation expense) was above

View original post here:
Valeant Beats on All Fronts – Analyst Blog

Related posts:

  1. Ironwood Pharma Beats on All Fronts – Analyst Blog
  2. Thoratec Beats with Ease; Ups View – Analyst Blog
  3. Shire Misses on All Fronts – Analyst Blog
  4. Maxim Beats, Guides in Line – Analyst Blog